SACHI evaluated the combination of savolitinib and TAGRISSO® for the treatment of patients with EGFRm, MET-amplified locally advanced or metastatic NSCLC after progression on EGFR TKI compared to ...

WBRT and systemic treatments (chemotherapy and/or EGFR TKIs) are the treatment options for polymetastatic involvement of the brain. Treatment approaches are not influenced by the timing of onset ...

Savolitinib is a targeted MET inhibitor already approved in China for specific NSCLC patients, and it has shown promise in overcoming resistance to EGFR ... US Tyrosine kinase inhibitor (TKI ...

It also is important to emphasize that amivantamab is a bispecific monoclonal antibody that targets EGFR and MET, and lazertinib is a third-generation TKI that targets EGFR. This dual inhibition ...

The IPASS (Iressa Pan-Asia Study) is the first large randomized clinical trial that compared first-line EGFR TKI therapy with chemotherapy. 1 In this study, 1,217 Asian non-smokers or former light ...

plus Lazcluze (lazertinib), a third-generation EGFR tyrosine kinase inhibitor (TKI), against AstraZeneca’s own third-generation EGFR-TKI Tagrisso (osimertinib) as a first-line treatment for locally ...

These patients are particularly sensitive to treatment with existing EGFR-TKIs, which block the cell signalling pathways that drive the growth of tumour cells. However, tumours almost always ...

The trial will continue to assess OS as a key secondary endpoint. While EGFR-TKIs have significantly improved outcomes in the 1st-line setting, mechanisms of resistance and disease progression are ...

Researchers from the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and the Shanghai Institute of Organic Chemistry have divulged EGFR (L858R/T790M/C797S triple mutant) and ...

EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach a higher concentration in brain tissues. Various reports and small studies ...